Work

Outcomes of t(11;14) light chain (AL) amyloidosis after autologous stem cell transplantation: benchmark for new therapies

Year: 2023

Type: article

Abstract: Systemic light chain (AL) amyloidosis is a clonal plasma cell disorder characterized by abnormal immunoglobulin light chain production, which forms insoluble fibrillary aggregates that deposit in tissues causing end-organ dysfunction. Cardiac involvement predominantly drives early mortality and influences patients’ functional status, treatment choice, and prognosis [ 1 ]. The management of AL amyloidosis focuses on clone eradication using plasma cell-directed therapies. Autologous stem cell transplant (ASCT) can result in a deep and durable response in carefully selected patients [ 2 ].

Source: Blood Cancer Journal

DOI: 10.1038/s41408-023-00945-0

Authors: Susan Bal, Noel Estrada-Merly, Luciano J. Costa, Muzaffar H. Qazilbash, Shaji Kumar, Anita D’Souza

Institutions: University of Alabama at Birmingham, Medical College of Wisconsin, The University of Texas MD Anderson Cancer Center, Mayo Clinic

Language: English

Topic: Amyloidosis: Diagnosis, Treatment, Outcomes

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $4,790